학술논문
[Efficacy and tolerance of direct-acting antiviral drugs for the treatment of hepatitis C in Joseph Raseta Befelatanana Teaching Hospital in Antananarivo, Madagascar].
Document Type
Academic Journal
Author
Razafindrazoto CI; Unité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.; Rasolonjatovo AS; Unité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.; Randriamifidy NH; Unité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.; Rabarioely SS; Unité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.; Rakotozafindrabe ALR; Unité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.; Rabenjanahary TH; Unité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.; Razafimahefa SH; Unité de soins, de formation et de recherche, hépato-gastro-entérologie et de médecine interne, Fianarantsoa, Madagascar. Faculté de médecine de Fianarantsoa, Université de Fianarantsoa, Madagascar.; Ramanampamonjy RM; Unité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.
Source
Publisher: Société francophone de médecine tropicale et santé internationale Country of Publication: France NLM ID: 9918227363206676 Publication Model: eCollection Cited Medium: Internet ISSN: 2778-2034 (Electronic) Linking ISSN: 27782034 NLM ISO Abbreviation: Med Trop Sante Int Subsets: MEDLINE
Subject
Language
French
Abstract
Objective: Our work aimed to assess the efficacy and safety of direct-acting antiviral drugs in the treatment of hepatitis C in Madagascar.
Methods: This retrospective clinical study was carried out from March 2018 to February 2020 in the hepato-gastro-enterology department of the University Hospital Center Joseph Raseta de Befelatanana.
Results: A total of 35 patients were included, out of which 24 received sofosbuvir/ledipasvir ± ribavirin, 10 sofosbuvir/ribavirin and one sofosbuvir/velpatasvir. Thirty-three patients were naïve to the treatment and 2 patients were initially treated with the sofosbuvir/ledipasvir combination. The sustained virologic response was 94% (33/35) in the general population, 23/25 in cirrhotic patients and 10/10 in non-cirrhotic patients. The sustained virologic response was 22/24 for sofosbuvir/ledipasvir ± ribavirin, 10/10 for sofosbuvir/ribavirin and 1/1 for sofosbuvir/velpatasvir. Adverse effects were observed in 13 patients, mainly asthenia and insomnia.
Discussion: The small number of patients with hepatitis C treatments and their limited financial resources are the main limits of this survey.
Conclusion: Direct-acting antivirals are effective and characterized by good tolerance in these Malagasy hepatitis C patients.
Competing Interests: L'auteur déclare ne pas avoir de conflit d'intérêt.
(Copyright © 2021 SFMTSI.)
Methods: This retrospective clinical study was carried out from March 2018 to February 2020 in the hepato-gastro-enterology department of the University Hospital Center Joseph Raseta de Befelatanana.
Results: A total of 35 patients were included, out of which 24 received sofosbuvir/ledipasvir ± ribavirin, 10 sofosbuvir/ribavirin and one sofosbuvir/velpatasvir. Thirty-three patients were naïve to the treatment and 2 patients were initially treated with the sofosbuvir/ledipasvir combination. The sustained virologic response was 94% (33/35) in the general population, 23/25 in cirrhotic patients and 10/10 in non-cirrhotic patients. The sustained virologic response was 22/24 for sofosbuvir/ledipasvir ± ribavirin, 10/10 for sofosbuvir/ribavirin and 1/1 for sofosbuvir/velpatasvir. Adverse effects were observed in 13 patients, mainly asthenia and insomnia.
Discussion: The small number of patients with hepatitis C treatments and their limited financial resources are the main limits of this survey.
Conclusion: Direct-acting antivirals are effective and characterized by good tolerance in these Malagasy hepatitis C patients.
Competing Interests: L'auteur déclare ne pas avoir de conflit d'intérêt.
(Copyright © 2021 SFMTSI.)